A Study of JNJ-88998377 for Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

NCT06470438 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

58

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphoma, Non-Hodgkin
Refractory B-Cell NHL
Relapsed B-cell NHL

Interventions

DRUG: JNJ-88998377

Sponsor

Janssen Research & Development, LLC